A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).

Ashley E. Ross,Andrew J. Armstrong,Christopher Michael Pieczonka,James Bailen,Ronald F. Tutrone,Matthew R. Cooperberg,Christian P. Pavlovich,Joseph Renzulli,Heather Haynes,Nadeem A. Sheikh,Neal D. Shore

A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).

2020

Ashley E. Ross
Andrew J. Armstrong
Christopher Michael Pieczonka
James Bailen
Ronald F. Tutrone
Matthew R. Cooperberg
Christian P. Pavlovich
Joseph Renzulli
Heather Haynes
Nadeem A. Sheikh
Neal D. Shore

321Background: Sip-T is an FDA approved, autologous cellular immunotherapy for mCRPC, manufactured by activating peripheral blood mononuclear cells collected by apheresis and culturing them with PA...

Keywords:

Pathology
Prostate cancer
Sipuleucel-T
Oncology
Castrate-resistant prostate cancer
Internal medicine
Medicine
Autologous Cellular Immunotherapy
Peripheral blood mononuclear cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations